Aviado · Research
Longevity Daily
Saturday, August 22, 2026
Listen
Today's Brief
Today's strongest theme is biological age — measuring it and moving it. A Yale meta-analysis puts specific numbers on which interventions reduce your epigenetic clock, naming semaglutide and metformin alongside diet-and-exercise combinations as the most potent tools. In the cognitive section, new findings on TIMP2 protein therapy point to a promising lever against brain neuroinflammation, while real-world lecanemab data should be required reading for any family navigating Alzheimer's treatment decisions. Also in today's issue: the first exercise-mimicking pill clears human safety testing, and Aviado Research offers its latest evidence-based deep-dive.
10 stories5 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
1 in 4 Lecanemab Patients Develop Brain Imaging Abnormalities in Real-World Use
Real-world data published in Neurology Open Access confirms what clinical trials warned: nearly 25% of patients treated with lecanemab for mild Alzheimer's disease or mild cognitive impairment develop amyloid-related imaging abnormalities (ARIA). ARIA ranges from asymptomatic to serious — including brain swelling and microbleeds — and the real-world incidence rate aligning with trial data closes the door on the hope that trial populations were unusually vulnerable. If you or a family member is considering lecanemab, this is a clear signal that regular MRI monitoring throughout treatment isn't optional — it's essential.
Read more →Brain Protein TIMP2 Resets Aging Immune Cells That Drive Neuroinflammation
New preclinical research shows that TIMP2 protein therapy can shift microglia — the brain's dedicated immune cells — away from their dysfunctional, inflammatory aging state toward a healthier, more protective profile. Microglia become progressively more inflammatory with age, releasing damaging signals that erode neural networks and accelerate cognitive decline across diseases from Alzheimer's to general dementia. This finding adds to mounting evidence that targeting neuroinflammation broadly, rather than chasing individual disease proteins, may be the higher-leverage strategy for preserving long-term brain health.
Read more →5 Emerging Strategies to Prevent Brain Aging: GLP-1s, Sleep Science, and the Gut-Brain Axis
Ahead of World Brain Day, NeurologyLive's clinical review spotlights five modifiable strategies gaining real traction in neurological disease prevention: addressing dementia risk factors early, GLP-1 receptor agonists (like semaglutide), optimizing sleep, nurturing the gut-brain axis, and deploying wearables for early detection. What's striking is how tightly this list overlaps with the broader longevity playbook — these aren't fringe biohacks, they're increasingly standard discussion in academic neurology. If you're only doing one of these five, the evidence now supports exploring the others.
Read more →Supplements & Compounds
Neuriva Doesn't Move the Needle on BDNF — A Close Look at the Popular Brain Supplement
Pharmacy Times reviewed published clinical data on Neuriva Original and found that at 42 days, plasma BDNF (brain-derived neurotrophic factor) levels showed no significant difference from placebo in a 128-participant trial (mean age 54). BDNF upregulation is the centerpiece of Neuriva's brain health claim. If you're taking Neuriva hoping to boost cognitive performance, this study is a significant red flag — and a timely reminder to verify whether your supplement's claimed mechanism is actually demonstrated in human data before you spend another month's worth on it.
Read more →Metformin Targets Inflammation via the Gut Microbiome — and May Mimic Caloric Restriction
A clinical review in Psychiatric Times traces metformin's healthspan effects to its modulation of the gut microbiome and downstream inflammatory pathways, noting that it appears to replicate key metabolic effects of caloric restriction — a validated longevity strategy in mammalian models. Preclinical data cited in the review also indicate metformin activates autophagy, the cellular cleanup process central to healthy aging. Metformin remains a prescription drug without an FDA longevity indication, but the mechanistic case for its off-label use among healthspan-focused clinicians continues to strengthen.
Read more →Research & Papers
Metformin and Semaglutide Outperform Diet and Exercise at Reversing Biological Age
A Yale-led analysis of clinical data asked a deceptively simple question: which interventions actually lower your biological age? The answer, drawn from multiple human studies, put prescription drugs at the top — metformin, semaglutide, and anti-TNF biologics produced the largest reductions in epigenetic age markers. Lifestyle came in as a solid second: any combination of a healthy diet (Mediterranean, low-carb, or low-fat) paired with regular exercise consistently moved epigenetic clocks in the right direction across the reviewed data. The practical read: you don't need a prescription to slow your biological clock, but the evidence suggests that drugs and lifestyle changes work better together than either does alone.
Read more →Aviado Research: Versioned Article — The Latest Evidence-Based Longevity Analysis
Aviado Research's latest piece delivers a carefully sourced review of a key longevity topic, going beyond the headline findings to give readers the mechanistic context and caveats needed to make informed decisions. As with all Aviado Research outputs, this analysis is built for readers who want to act on the science, not just follow it.
Read the full Aviado analysis →Lifestyle & Nutrition
Your Waist Measurement May Matter More Than Your BMI for Heart Disease Risk
New research shows that waist circumference and waist-to-hip ratio reclassify cardiovascular risk across all BMI categories — including people who register as normal weight. That means you can have a textbook-healthy BMI while carrying enough visceral fat to meaningfully elevate your heart disease risk, or inversely, carry extra body weight without the dangerous central fat distribution. The actionable implication: start measuring your waist alongside your weight, and take central adiposity seriously regardless of what the scale tells you.
Read more →Industry & Policy
The First 'Exercise Pill' Reaches Human Trials — ENV-308 Passes Phase 1 Safety in 88 Volunteers
Enveda Biosciences has completed a Phase 1 trial of ENV-308, the first drug designed to mimic Lac-Phe — a peptide hormone naturally released during vigorous exercise — with a clean safety profile across 88 healthy volunteers. Unlike prior exercise mimetics developed from metabolic targets, ENV-308 was built directly from the biochemistry of what exercise actually produces in the body. Phase 2 will test whether it can help people sustain weight loss after stopping GLP-1 drugs, addressing one of the most pressing gaps in the booming GLP-1 space.
Read more →XPrize Healthspan Is Putting Rapamycin, Spermidine, and Competing Longevity Protocols to a Real Test
The Mount Sinai team competing in XPrize Healthspan is testing a combination of rapamycin and spermidine — a naturally occurring polyamine that modulates aging-related inflammation via autophagy — as part of a rigorous, competition-structured evaluation of the field's top protocols. The XPrize format, with defined endpoints and competitive pressure, is positioned to finally generate the kind of head-to-head comparative human data that longevity medicine has lacked. Results from competing teams are expected to meaningfully reshape which interventions have the strongest evidence behind them.
Read more →